Axa S.A. Eagle Pharmaceuticals, Inc. Transaction History

Axa S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Feb 14, 2023	SELL	$26.42 - $47.12 $79,260 - $141,360	-3,000 Reduced 11.88%	22,250 $587,000
Q3 2022 Nov 14, 2022	SELL	$26.42 - $47.12 $79,260 - $141,360	-3,000 Reduced 11.88%	22,250 $588,000
Q2 2022 Feb 14, 2023	SELL	$41.26 - $51.35 $278,505 - $346,612	-6,750 Reduced 21.09%	25,250 $1.12 Million
Q2 2022 Aug 15, 2022	SELL	$41.26 - $51.35 $278,505 - $346,612	-6,750 Reduced 21.09%	25,250 $1.12 Million
Q1 2022 Feb 14, 2023	BUY	$44.58 - $52.6 $434,655 - $512,850	9,750 Added 43.82%	32,000 $1.58 Million
Q1 2022 May 13, 2022	BUY	$44.58 - $52.6 $1.43 Million - $1.68 Million	32,000 New	32,000 $1.58 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.